Weerapong Phumratanaprapin

Randomized Trial of 3-Dose Regimens of Tafenoquine (WR238605) versus Low-Dose Primaquine for Preventing Plasmodium vivax Malaria Relapse

Douglas S. Walsh, Polrat Wilairatana, D. B. Tang et al. · Clinical Infectious Diseases · 2004 · 100 citations · Full text

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

William HK Schilling, Podjanee Jittamala, James A Watson et al. · The Lancet Infectious Diseases · 2023 · 85 citations · Full text

Cytokine Expression in Dengue Fever and Dengue Hemorrhagic Fever Patients with Bleeding and Severe Hepatitis

Hisham Ahmed Imad, Weerapong Phumratanaprapin, Benjaluck Phonrat et al. · American Journal of Tropical Medicine and Hygiene · 2020 · 74 citations · Full text

Immunology, Severe Hepatitis, Confirmed Dengue Infection +22

Rabies Exposure Risk among Foreign Backpackers in Southeast Asia

Watcharapong Piyaphanee, Prapimporn Chattranukulchai Shantavasinkul, Weerapong Phumratanaprapin et al. · American Journal of Tropical Medicine and Hygiene · 2010 · 68 citations · Full text

Vaccination, Rabies Exposure Risk, Infectious Disease Epidemiology +14

Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection

Chayanee Setthapramote, Tadahiro Sasaki, Orapim Puiprom et al. · Biochemical and Biophysical Research Communications · 2012 · 61 citations

Vaccination, Medicine, Humoral Response +8